What InVivo Biotech Services GmbH does

InVivo BioTech Services GmbH is a German contract manufacturing and development organization (CDMO) headquartered in Hennigsdorf, Brandenburg, with a second production site in Berlin-Kreuzberg. Founded in 1999 and operating with approximately 80 employees, the company specializes in custom bioproduction of monoclonal antibodies and recombinant proteins, serving global diagnostics manufacturers, biopharmaceutical companies, and academic spin-offs. Its facility footprint supports bioreactor-scale production from 2 to 100 liters with antibody yields up to 1 kg, using CHO and HEK mammalian cell culture as well as E. coli bacterial expression systems.

The technology stack centers on classical hybridoma development, recombinant expression, and proprietary instrumentation including the Beacon optofluidic single-cell screening platform for antibody discovery, SPR-32 Pro for molecular interaction analysis, MALDI Biotyper for biomolecule QC, and QTOF mass spectrometry for de novo antibody sequencing in collaboration with Bruker Daltonics and CeMOS. Custom services span antibody development, monoclonal and recombinant antibody production, recombinant protein production, cell line development, hybridoma development, cell banking, lyophilization, protein labeling, and DNA design. These capabilities are supplemented by a catalog portfolio comprising in vivo antibodies, isotype controls, neuroscience biomarker antibodies (Tau, Beta Amyloid, PrP, Alpha Synuclein, TDP-43), recombinant proteins, and SARS-CoV-2 antigens and antibodies.

Since 2017, InVivo has operated as a wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR), combining its bioproduction expertise with Bruker's analytical instrument ecosystem. Revenue is generated primarily through quote-based fee-for-service contracts with multi-year engagements and one-time catalog purchases through a website storefront and regional distributor network (2BScientific for UK, Sanbio for BeNeLux, ARP for the US). ISO 9001:2015 and ISO 13485:2016 certifications underpin regulatory-grade supply to FDA-approved diagnostic kit manufacturers. The company is led by Managing Directors Olaf Degen and Jennifer Suhr, with commercial leadership under Dr. Moath Al-Mekhlafi.

Name

InVivo Biotech Services GmbH

Legal name

InVivo BioTech Services GmbH

Website

https://invivo.de

Company type

Private

Founded year

1999

Operating status

Operating

Short description

InVivo BioTech Services GmbH is a German CDMO with approximately 80 employees that provides custom monoclonal antibody and recombinant protein production, antibody discovery via Beacon optofluidic screening, and analytical characterization services to global diagnostics manufacturers, biopharmaceutical companies, and academic research institutions. It is a wholly-owned subsidiary of Bruker Corporation since 2017.

Ownership category

akta.pro rank

Product category

Contract Bioproduction / CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Contract antibody manufacturing
• Monoclonal antibody services
• Recombinant protein production
• Biopharmaceutical CDMO
• Cell line development

Headquarters

HQ city

Hennigsdorf

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Custom Antibody Production Services: Contract manufacturing of monoclonal antibodies from hybridoma cells and recombinant antibody production. Full-service from antigen production to final immunoassay kit delivery.
2. Recombinant Protein Production: Production of recombinant proteins in bacterial (E. coli) and mammalian (CHO, HEK) expression systems for research, diagnostic, and preclinical use.
3. Cell Line Development: Development of stable cell lines for non-GMP applications and stable CHO cell pools for scalable production.
4. Catalog Products: Sale of in vivo antibodies, neuroscience biomarkers (Tau, Beta Amyloid, PrP, Alpha Synuclein, TDP-43), recombinant proteins, SARS-CoV-2 antigens and antibodies, oncology biomarkers.
5. Antibody Development Services: Rapid antibody discovery using Beacon platform, hybridoma workflows, and antibody characterization services including SPR analysis, ELISA, and custom immunoassay development.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

InVivo BioTech Services GmbH is a German contract manufacturing organization providing custom bioproduction services for monoclonal antibodies, recombinant antibodies, and recombinant proteins using mammalian (CHO, HEK) and bacterial (E. coli) expression systems. The company offers end-to-end support from antibody discovery (via its Beacon optofluidic single-cell screening platform and hybridoma workflows) through antibody and protein production, cell line development, and analytical characterization (SPR, MALDI-TOF, QTOF sequencing), serving diagnostics manufacturers, biopharmaceutical companies, and academic research customers. It also sells a catalog portfolio of in vivo grade antibodies, neuroscience biomarker antibodies, recombinant proteins, and SARS-CoV-2 antigens.

Product overview

InVivo BioTech Services GmbH is a contract manufacturing organization (CMO/CDMO) providing custom bioproduction and antibody development services. The company operates as a single unified service offering encompassing both proprietary catalog products and fee-for-service contract manufacturing. The product portfolio includes: (1) catalog products under the in vivo Antibodies, Neuroscience Biomarker, Antibodies, Proteins, and SARS-CoV-2 sub-brands; (2) technology platforms including the Beacon optofluidic platform for antibody discovery, Bioproduction platform for scalable manufacturing, and analytical platforms (SPR-32 Pro, MALDI Biotyper); and (3) comprehensive services spanning antibody development, antibody production (monoclonal and recombinant), recombinant protein production, cell line development, and additional services including hybridoma development, cell banking, lyophilization, protein labeling, DNA design, and antibody sequencing. The company is a Bruker Group subsidiary since 2017 and serves global diagnostics and biopharmaceutical companies as well as academic institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• in vivo Antibodies Antibodies specifically developed and produced for in vivo applications including preclinical research models, including labeled cancer antigens and oncological antibodies.
• Isotype Controls Control antibodies used to verify specific binding in immunological assays and in vivo experiments, ensuring accurate interpretation of research results.
• Neuroscience Biomarker Antibodies (Tau, Beta Amyloid, PrP, Alpha Synuclein, TDP-43) Antibodies targeting key neurodegenerative disease biomarkers including Tau, Beta Amyloid, PrP (Prion Protein), Alpha Synuclein, and TDP-43, used in Alzheimer's, Parkinson's, ALS, and prion disease research and diagnostic development.
• Monoclonal Antibodies Monoclonal antibodies produced from hybridoma cells, providing consistent, high-specificity antibodies for research, diagnostic, and preclinical applications.
• Recombinant Antibodies Recombinantly produced antibodies offering superior consistency and scalability compared to traditional hybridoma-derived antibodies, with defined sequences and reproducible production processes.
• Recombinant Proteins Recombinant proteins produced in bacterial (E. coli) and mammalian cell expression systems for research and diagnostic applications.
• SARS-CoV-2 Antigens and Antibodies Recombinant SARS-CoV-2 antigens including Spike protein variants (RBD, S1, S2 subdomains) and corresponding antibodies for COVID-19 in vitro diagnostic development.
• Stabilin-1 / CLEVER-1 Monoclonal Antibody Cancer biomarker monoclonal antibody (Stabilin-1 / CLEVER-1) added to the oncology catalog for cancer research and immunotherapy development.
• Oncology Antibodies Portfolio Cancer biomarker antibodies and immune checkpoint inhibitor antibodies for preclinical oncology research and in vivo studies.
• Antibody Development Service Full-service antibody discovery from antigen production to validated antibody candidate delivery, using the Beacon optofluidic platform for rapid single-cell screening and traditional hybridoma workflows.
• Monoclonal Antibody Production Service Custom production of monoclonal antibodies from hybridoma cells with scalable bioreactor capacities up to 100L, delivered serum-free, endotoxin-free, and aggregate-free.
• Recombinant Antibody Production Service Production of recombinant antibodies in mammalian cell systems (CHO, HEK) with high reproducibility and scalability from 2–100L cultivations.
• Recombinant Protein Production Service Recombinant protein production using bacterial (E. coli) and mammalian (CHO, HEK) expression systems with scalable bioreactor capacities, supporting research, diagnostic, and preclinical applications.
• Cell Line Development Service Development of stable cell lines for non-GMP applications, including stable CHO cell pools and monoclonal CHO cell lines for consistent long-term protein production.
• Hybridoma Development Service Development of hybridoma cell lines producing monoclonal antibodies through traditional somatic hybridization methodology.
• Cell Banking Service Secure storage and preservation of cell lines including master cell banks and working cell banks.
• Lyophilization Service Freeze-drying services for stabilization of antibodies and proteins, extending shelf life and enabling room temperature storage.
• Protein Labeling Service Conjugation and labeling services for antibodies including fluorescent labels, enzymes, and other tags for diagnostic and research applications.
• DNA Design and Larger Scale DNA Preparation Service Custom DNA sequence design for optimized gene synthesis and expression vector construction, plus high-volume plasmid DNA preparation for large-scale production needs.
• Antibody Sequencing & Optimization Service De novo antibody sequencing using QTOF mass spectrometry and sequence optimization services for improved affinity and developability.

Quantifiable outcome

• Accelerated antibody discovery timelines compared to traditional hybridoma or phage display approaches
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, flagship and minor.

• CeMOS (Center for Mass Spectrometry and Optical Spectroscopy)coreStrategic or Co-development Partner · 8 April 2021Demonstrated complete de novo sequencing of human monoclonal IgG using QTOF mass spectrometry in collaboration with Bruker Daltonics and InVivo.
• Bruker DaltonicscoreTechnology or Integration · 8 April 2021Collaboration on QTOF mass spectrometry for de novo antibody sequencing. Bruker provides analytical technology integrated with InVivo's antibody production capabilities.
• 2BScientificcoreChannel Partner/ Reseller/ DistributorUK-based distributor delivering high-quality life science reagents with customer-first approach. Connects researchers with trusted global brands for reliable, innovative solutions.
• SanbiocoreChannel Partner/ Reseller/ DistributorTrusted life science distributor and manufacturer for BeNeLux region, offering high-quality research and diagnostic products alongside expert technical support.
• ARPcoreChannel Partner/ Reseller/ DistributorProvides high-quality life science reagents and lab products with expert, responsive support in the US. Trusted by researchers across academia and industry.
• Bruker CorporationflagshipOthersGlobal parent company since 2017. Bruker is a global leader in scientific instrumentation, delivering advanced analytical solutions for molecular and materials research, diagnostics, and industrial applications. InVivo operates as a Bruker company.
• CiteAbminorGTM or Marketing PartnerAntibody search platform that helps researchers find and compare antibodies and experimental reagents, backed by citation data.
• BiocompareminorGTM or Marketing PartnerLeading life sciences resource connecting researchers with trusted product information, reviews, and industry insights.
• PSL Alliance (Pivotal Scientific)coreStrategic or Co-development PartnerAlliance managed by Pivotal Scientific, connecting innovative life science companies to foster global partnerships and accelerate growth across RUO and IVD sectors. InVivo is Platinum Sponsor.
• Therawis DiagnosticsminorStrategic or Co-development PartnerMunich-based biotech company specializing in immunology and precision medicine, focused on developing predictive diagnostics for cancer and complex diseases.
• Faron PharmaceuticalsminorStrategic or Co-development PartnerClinical-stage biopharmaceutical company pioneering macrophage-targeting immunotherapies to transform cancer treatment.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Lonza Group: Global tier-1 biologics CDMO providing mammalian cell line development, GMP manufacturing, and antibody production — represents the upper end of InVivo's competitive set and the scale InVivo does not match.
• GenScript ProBio: Broader CDMO and biologics services platform from the GenScript group offering antibody discovery, cell line development, and GMP manufacturing — overlaps with InVivo's discovery-to-preclinical workflow at greater scale.
• Cell Signaling Technology (CST): Established antibody manufacturer with deep catalog across signaling pathways, neuroscience, and immunology — competes head-on with InVivo's antibody catalog for the same biopharma/research customers.
• R&D Systems (Bio-Techne): Major catalog supplier of proteins and antibodies across research and bioprocess — adjacent to InVivo's catalog antibody and recombinant protein product lines.
• Abcam: Global antibody reagent incumbent with an enormous catalog of validated antibodies used by research and IVD developers — directly overlaps InVivo's catalog antibody business and competes for the same research/IVD antibody wallets.

Direct peers

• Trenzyme: European (German) contract service provider offering recombinant protein expression, cell line development, and antibody services — direct boutique CDMO peer of similar size and geographic profile.
• ProMab Biotechnologies: US-based custom monoclonal antibody and recombinant protein production services company — direct functional equivalent of InVivo's custom antibody and hybridoma production service lines.
• Atlas Antibodies: Swedish vendor of highly validated antibodies and protein atlas reagents, including neuroscience biomarker products — a direct niche peer to InVivo's neuroscience biomarker catalog (Tau, Alpha Synuclein, TDP-43, etc.).
• Synaptic Systems: German antibody manufacturer specializing in neuroscience and synaptic biology research reagents — mirrors InVivo's neuroscience biomarker catalog focus and German Mittelstand quality positioning.
• Eurogentec (Kaneka Eurogentec): European biologics CDMO offering custom antibody production, recombinant protein expression, and oligonucleotide synthesis — directly comparable to InVivo's CDMO service portfolio and similarly European-rooted.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/invivo-biotech-services-gmbh

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InVivo Biotech Services GmbH